Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.160
-0.330-3.89%
Volume:233.85M
Turnover:1.93B
Market Cap:94.02B
PE:22.13
High:8.720
Open:8.410
Low:7.990
Close:8.490
52wk High:11.454
52wk Low:4.463
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:2.56
T/O Rate:2.03%
Dividend:0.24
Dividend Rate:2.94%
EPS(LYR):0.369
ROE:10.83%
ROA:5.65%
PB:2.50
PE(LYR):22.13
PS:3.17

Loading ...

AstraZeneca Projects Double-Digit EPS Growth Following $18.5 Billion CSPC Pharma Partnership

Deep News
·
Feb 10

CSPC Pharmaceutical Group Stock Rises 5.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Feb 10

Biopharmaceutical Stocks Show Broad Gains with CSPC PHARMA Leading with Over 7% Rise

Deep News
·
Feb 10

CSPC PHARMA Shares Climb Over 3% as Analysts Foresee Additional Out-Licensing Deals for EGFR ADC and R&D Platform

Stock News
·
Feb 09

Tirzepatide Crowned as New "Blockbuster Drug King" with Rapid Commercial Value Release Expected for Weight Loss Medications

Stock News
·
Feb 05

CSPC Pharmaceutical Group Stock Falls 2.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Feb 04

BUZZ-CSPC Pharmaceutical jumps most in eight months on hypertension drug approval

Reuters
·
Feb 03

HK Stock Movement | CSPC PHARMA (01093) Rises Nearly 6% as Institutions Expect BD Deals to Support Earnings and Dividends

Stock News
·
Feb 03

CSPC PHARMACEUTICAL GROUP LIMITED (01093) Issues Monthly Return for January 2026

Bulletin Express
·
Feb 02

BREAKINGVIEWS-Asian investment banking is at an inflection point

Reuters
·
Feb 02

CSPC Pharmaceutical Group Receives Approval for Clevidipine Injectable Emulsion

Reuters
·
Feb 02

CSPC PHARMA (01093) Receives Drug Registration Approval for Clevidipine Butyrate Lipid Emulsion Injection

Stock News
·
Feb 02

CSPC Pharmaceutical - Approval Granted by Nmpa.

THOMSON REUTERS
·
Feb 02

CSPC Pharmaceutical - Clevidipine Injectable Emulsion Approved in China

THOMSON REUTERS
·
Feb 02

CSPC Pharmaceutical Group Stock Slips 4.7% in Hong Kong

Dow Jones
·
Feb 02

Bank of America Securities Raises CSPC PHARMA (01093) Target Price to HK$9.1, Reiterates "Underperform" Rating

Stock News
·
Feb 02

BREAKINGVIEWS-AstraZeneca escalates Big Pharma’s China land grab

Reuters
·
Feb 02

CMSC International Reiterates "Neutral" Rating on CSPC PHARMA (01093) as Chinese Innovative Drugs Enter Global Pipeline

Stock News
·
Feb 02

CICC Maintains "Outperform" Rating on CSPC PHARMA (01093) Following Major AstraZeneca Collaboration

Stock News
·
Feb 02

Inking $18.5 Billion Mega-Deal, Why Did CSPC PHARMA Face Sell-Off? "Smart Money" Quietly Accumulates via HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION TRADING OPEN ENDED INDEX SECURITIES INVES (520880)

Deep News
·
Feb 01